Elutia (ELUT)
NASDAQ:ELUT
Want to see ELUT full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.26Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized meaningful strategic and operational progress: positive regulatory interactions, the automated manufacturing platform coming online with an >80% gross margin target, improved reported gross margins, clear commercial validation and a large $1.5B market opportunity. However, current revenues remain small ($3.1M), one legacy product (SimpliDerm) saw a ~19% decline, operating expenses exceed revenue, and GAAP net loss widened significantly (≈+92%), with continued reliance on strategic transactions and future FDA approvals to de-risk the story. On balance, the forward-looking operational and regulatory advances and the sizable market opportunity outweigh near-term financial shortfalls, but execution and timing risks remain.Company Guidance
Regulatory Progress and Clear Timeline
Productive and collaborative FDA interactions increased management confidence in submissions; company anticipates NXT-41 clearance in Q4 2026 and NXT-41x clearance in H1 2027, improving visibility on key milestones.
Automated Manufacturing Platform Brought Online
Core automated production equipment and robotic coating system are operational, supporting scalability, reproducibility and quality control; targeted gross margin above 80% at scale, creating pricing room vs incumbents.
Large, Validated Market Opportunity
Addressable U.S. breast reconstruction market estimated at ~$1.5 billion (≈168,000 procedures/year); biologic mesh used in >85% of implant-based reconstructions; legacy product price per breast ~$7,500–$9,500; postoperative infection rates 15%–20% and serious complications common, underlining unmet need.
Commercial Validation and Concentrated Go-to-Market
Direct surgeon engagement confirmed clinical need and lack of meaningful innovation; market concentration: ~1,800 hospitals perform reconstructions, ~585 hospitals account for ~75% of the market and top 50 centers represent >$300 million of spend, supporting targeted commercialization strategy.
Improved Margins and Favorable Product Mix
GAAP gross margin improved to 58% from 47% (+11 percentage points); adjusted gross margin improved to 67% from 56% (+11 percentage points), driven by favorable product mix and price improvements.
Strong Growth in Cardiovascular Business
Cardiovascular revenue grew to $1.0 million from $0.3 million year-over-year (≈+233%), with an 85% gross margin in the quarter.
Solid Liquidity Position with Near-Term Upside
Cash on hand of $28.5 million plus $8.0 million escrow from prior BioEnvelope divestiture, totaling $36.5 million available; management believes capital position supports planned regulatory and operational milestones.
Proven Track Record and Prior Monetization
Management has prior commercialization and monetization success: sale of first-generation product EluPro to Boston Scientific for $88 million demonstrates exit potential for differentiated drug-eluting biomatrix technology.
ELUT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ELUT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $1.04 | $1.03 | -0.96% |
Mar 11, 2026 | $1.09 | $1.15 | +5.50% |
Nov 06, 2025 | $0.94 | $0.90 | -4.99% |
Aug 14, 2025 | $2.15 | $2.02 | -6.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Elutia (ELUT) report earnings?
Elutia (ELUT) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Elutia (ELUT) earnings time?
Elutia (ELUT) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELUT EPS forecast?
ELUT EPS forecast for the fiscal quarter 2026 (Q2) is -0.15.